PNC-27
Also known as: p53-Derived Peptide, Death-Inducing Peptide, Anti-Cancer Peptide
⚠
Research-based dosing - under active validation
Based on current literature. Variability exists across study populations.
Under Review
Typical Dosage
•
Preclinical research only
•
no established human dosing
Administration
Injection
Administration Schedule
N/A
How It Works
Synthetic 27-amino acid peptide from p53 transactivation domain. Directly inhibits anti-apoptotic proteins (Bcl-2/Bcl-xL) in cancer cells.
Research Applications
- Cancer cell apoptosis induction
- Bcl-2 family protein inhibition
- p53-mutant cancer models
- Mitochondrial apoptosis research
Research Protocol Summary
Typical Protocol Duration
N/A
Half-Life
Not Well Characterized In Vivo
Protocol Notes
•
Preclinical studies show selectivity for cancer cells over normal cells.
•
No human dosing established.
Citations & Sources
Loading citations…
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.